English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/198669
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

AuthorsCastro, Javier de; González-Larriba, J. L.; Vázquez, Sergio; Massutí, Bartomeu; Sánchez-Torres, J. M.; Dómine, Manuel; Garrido, Pilar; Calles, A.; Artal, A.; Collado, Rosa; García, R.; Sereno, M.; Majem, M.; Macías, J. A.; Juan-Vidal, Óscar; Gómez-Codina, J.; Hernández, B.; Lázaro, M.; Ortega, A. L.; Cobo, M.; Trigo, José Manuel; Carcereny Costa, Enric; Rolfo, C.; Macia, S.; Muñoz, J.; Diz, P.; Méndez, M.; Rosillo, F.; Paz-Ares, Luis ; Cardona, J. V.; Isla, María Dolores
KeywordsNon-squamous NSCLC
First-line treatment
Bevacizumab
Bevacizumab maintenance therapy
Routine clinical practice setting
Observational study
Issue DateFeb-2017
PublisherSpringer Nature
CitationClinical and Translational Oncology 19(2): 219-226 (2017)
Abstract[Background/Aim] First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.
[Patients and methods] This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.
[Results] Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.
[Conclusion] Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
Publisher version (URL)http://dx.doi.org/10.1007/s12094-016-1527-8
URIhttp://hdl.handle.net/10261/198669
DOIhttp://dx.doi.org/10.1007/s12094-016-1527-8
Identifiersdoi: 10.1007/s12094-016-1527-8
issn: 1699-048X
e-issn: 1699-3055
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.